Projects

Chosen filters:
Chosen filters:

1 - 10 of 693 results

Sorteren op
Search term:

Stichting Alzheimer SAO-FRA: "Herpesvirus-induced neuroinflammation in the peripheral nervous system (PNS) as a 'distant' trigger of Alzheimer's disease" Ghent University

Kathlyn Laval
Department of Translational Physiology, Infectiology and Public Health

AlzheimerU+2019s disease (AD) is a neurodegenerative disorder affecting 26 million people worldwide. To date, there is no cure and current therapies are not effective in delaying progression. Thus, there is an

urgent need to change the way of looking at the disease and to rethink possible therapies. Herpes simplex virus type 1 (HSV1) has recently received growing attention for its role in AD. HSV1 infects the mouth and invades ...

Research of genetic, clinical and neuropathological characteristics of neurodegenerative brain diseases with focus on Alzheimer's disease and frontotemporale dementia University of Antwerp

Christine Van Broeckhoven
VIB CMN - Neurodegenerative Brain Diseases Group
This funding will be used for the extension of the PhD mandates of Elisabeth Hens and Helena Gossye with one year from October 1st 2020 to September 30th 2021 (third PhD year). Both are PhD students in the group of Professor Christine Van Broeckhoven. Both PhD students are medical doctors and neurology trainees. The main aim of their project is to examine in dept the genotype - phenotype correlation of familial and sporadic patients, carrying ...

Role of metals and metal containing biomolecules in neurodegenerative diseases such as Alzheimer's disease Ghent University

This European project aims to overcome the limitations caused by a lack of reference measurement procedures for established Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF), while also introducing reference measurement procedures for potential new blood-based AD biomarkers, such as metals and metalloproteins. The traceability of the provided reference measurement procedures will provide comparability between laboratories.

Role y-secretase heterogeneity in intracellular AB production, lysosomal toxicity, and pathogenesis: contribution of familial Alzheimer’s disease mutations in presenilins and late onset Alzheimer’s disease risk factors KU Leuven

Wim Annaert
Laboratory of Membrane Trafficking (VIB-KU Leuven)

Alzheimer’s disease (AD) is characterized by amyloid β (Aβ) plaques and tangles. These hallmarks appear relatively late in disease stirring the debate whether they are a consequence of earlier pathogenic processes. Herein intracellular Aβ accumulation precede their formation, and correlates better with synaptic dysfunction and cognitive decline. Our recent data suggest that the composition of Aβ yielding γ-secretase complexes plays a role in ...

Role of Presenilin2 deficiency and familial Alzheimer's disease mutants in intracellular Abeta accumulation and Alzheimer's disease pathology KU Leuven

Wim Annaert
Laboratory of Membrane Trafficking (VIB-KU Leuven)

Alzheimer’s disease (AD) is characterized by the progressive build-up of amyloid-beta (AB) in plaques. gamma-Secretase processing releases AB from the amyloid precursor protein and comes in different flavours because of the existence of two presenilins and APH1 isoforms. Distinct complexes generate slightly different AB profiles and familial AD linked mutations in PSENs shift the production to longer AB species which aggregate more easily. ...

Investigation of the disease modification potential of early life prolonged antiepileptogenic treatments in established Alzheimer's disease mouse models. University of Antwerp

Sebastiaan Engelborghs
Neurochemistry and behaviour
Alzheimer's disease (AD) is the most frequent global cause of severe cognitive impairment. Epilepsy, characterised by repetitive unprovoked seizures, is more prevalent in AD patients than in healthy controls. We hypothesise that subclinical epileptic phenomena occur in a considerable part of AD patients which aggravates cognitive decline. We therefore propose an intervention with antiseizure drugs early in the disease course as a possible ...

Investigation of the disease modification potential of early life prolonged antiepileptogenic treatments in established Alzheimer's disease mouse models. Vrije Universiteit Brussel

Ilse Smolders
Middelheim General Hospital, University of Antwerp, Pharmaceutical and Pharmacological Sciences
Alzheimer's disease (AD) is the most frequent global cause of severe cognitive impairment. Epilepsy, characterised by repetitive unprovoked seizures, is more prevalent in AD patients than in healthy controls.

We hypothesise that subclinical epileptic phenomena occur in a considerable part of AD patients which aggravates cognitive decline. We therefore propose an intervention with antiseizure drugs early in the disease course as a ...

Investigating the influence of astrocytes on functional network disruptions and amyloid pathology at early disease stages in a mouse model of Alzheimer's disease KU Leuven

Bart De Strooper
Laboratory for the Research of Neurodegenerative Diseases (VIB-KU Leuven)

Alzheimer’s disease (AD) is the most common type of dementia in the elderly population. There are symptomatic treatments that can delay further symptom progression, but currently there is no cure. Efficient treatment development requires a) knowledge on early mechanisms during AD progression and b) tools that allow follow up of disease and treatment effects in a clinically translational way. AD pathology includes the formation of toxic ...

The role of protein aggregate maturation in Alzheimer's disease and other neurodegenerative disorders and its potential for disease monitoring and differential diagnosis. KU Leuven

Dietmar Thal
Translational Cell & Tissue Research

This project aims at identifying changes in the composition of Alzheimer’s disease (AD)-related protein aggregates throughout preclinical and clinical stages of the disease. Moreover, we want to find out whether such “maturation changes” can be clinically detected by specific biomarkers or may represent potential therapeutic targets. To address these aims we analyze human brain tissue samples from non-AD, preclinical AD, and symptomatic AD ...

Prospective head-to-head comparison of cardiac [18F]-MFBG PET versus [123I]-MIBG SPECT in the differentiation between Parkinson’s disease and multiple system atrophy and between dementia with Lewy bodies and Alzheimer’s disease. KU Leuven

Koen Van Laere
Nuclear Medicine & Molecular Imaging
The present study will be sponsored by the KU Leuven with Koen Van Laere, Prof MD PhD DSc, as its principal investigator.The purpose is a prospective head-to-head comparison of [18F]-MFBG cardiac innervation in the differential diagnosis of Parkinson’s disease and dementia with Lewy Bodies, compared to cardiac innervation measured by [123I]-MIBG cardiac imaging and brain dopamine transporter availability measured by [18F]-PE2I PE.Primary ...